From MarketBeat:



Analysts have given Sight Sciences, Inc. a rating of “Hold” with a target price of $4.60. The company’s stock has received several comments from brokerages, including downgrades from “overweight” to “neutral” and “outperform” to “market perform”. The company’s stock performance has shown a decline, with a 12-month low of $1.04 and a high of $15.30. Despite a negative return on equity and a negative net margin, analysts predict that Sight Sciences will post a negative earnings per share for the current fiscal year. Insider transactions include a director acquiring shares of the company’s stock. Several hedge funds have made changes to their positions in SGHT. Sight Sciences, Inc. is an ophthalmic medical device company that focuses on developing and commercializing surgical and nonsurgical technologies for the treatment of eye diseases. The article also includes an alert from MarketBeat and a recommendation to consider other stocks instead of investing in Sight Sciences, Inc.



Original: Sight Sciences, Inc. (NASDAQ:SGHT) Given Average Recommendation of “Hold” by Analysts